Barclays PLC Increases Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Barclays PLC boosted its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 87.8% during the third quarter, HoldingsChannel.com reports. The firm owned 324,472 shares of the company’s stock after purchasing an additional 151,685 shares during the period. Barclays PLC’s holdings in Xeris Biopharma were worth $925,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of XERS. Walleye Capital LLC purchased a new position in shares of Xeris Biopharma during the 3rd quarter valued at approximately $3,197,000. Renaissance Technologies LLC raised its position in Xeris Biopharma by 33.9% during the second quarter. Renaissance Technologies LLC now owns 1,351,640 shares of the company’s stock worth $3,041,000 after acquiring an additional 342,300 shares during the period. Geode Capital Management LLC lifted its holdings in Xeris Biopharma by 2.9% during the third quarter. Geode Capital Management LLC now owns 3,333,470 shares of the company’s stock valued at $9,502,000 after purchasing an additional 93,091 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Xeris Biopharma in the third quarter valued at about $237,000. Finally, Bank of New York Mellon Corp grew its position in shares of Xeris Biopharma by 23.0% in the second quarter. Bank of New York Mellon Corp now owns 428,554 shares of the company’s stock valued at $964,000 after purchasing an additional 80,015 shares during the period. 42.75% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

XERS has been the topic of a number of research reports. HC Wainwright raised their price target on shares of Xeris Biopharma from $6.00 to $6.60 and gave the company a “buy” rating in a research note on Monday, November 11th. Piper Sandler cut Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 target price for the company. in a report on Monday, November 11th.

Xeris Biopharma Stock Down 2.4 %

Shares of NASDAQ XERS opened at $3.20 on Wednesday. The firm has a 50-day simple moving average of $3.35 and a 200-day simple moving average of $2.92. The stock has a market capitalization of $477.06 million, a price-to-earnings ratio of -7.11 and a beta of 2.62. Xeris Biopharma Holdings, Inc. has a 52 week low of $1.69 and a 52 week high of $3.87.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.